Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Assets (2016 - 2025)

Historic Current Assets for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $21.3 million.

  • Cytosorbents' Current Assets rose 2841.19% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 2841.19%. This contributed to the annual value of $21.6 million for FY2024, which is 1493.99% down from last year.
  • As of Q3 2025, Cytosorbents' Current Assets stood at $21.3 million, which was up 2841.19% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Current Assets registered a high of $79.6 million during Q1 2021, and its lowest value of $16.6 million during Q3 2024.
  • In the last 5 years, Cytosorbents' Current Assets had a median value of $25.4 million in 2025 and averaged $37.0 million.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 11219.38% in 2021, then crashed by 5549.13% in 2022.
  • Over the past 5 years, Cytosorbents' Current Assets (Quarter) stood at $64.3 million in 2021, then plummeted by 47.5% to $33.8 million in 2022, then dropped by 24.77% to $25.4 million in 2023, then dropped by 14.94% to $21.6 million in 2024, then fell by 1.35% to $21.3 million in 2025.
  • Its last three reported values are $21.3 million in Q3 2025, $23.0 million for Q2 2025, and $25.4 million during Q1 2025.